Therapeutic RNA vaccines in cancer Immunotherapy

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/37/d8/7a/37d87ae2-af3e-0213-e439-57905d10d0b0/mza_13754466389719225512.jpg/600x600bb.jpg

Immuno Oncology Talks

Sanofi

11 episodes

7 months ago

In the current episode of “Immuno Oncology Talks”, we discuss the clinical challenges and future perspectives of CAR-T cells with our experts, from the Oslo University Hospital in Norway, Dr Else Marit Inderberg and Dr Sébastien Wälchli. Dr Inderberg is the head of the immunomonitoring at the hospital and has a research focus on novel immunotherapies, and Dr Wälchli is leading the CAR development platform. MAT-BE-2400334 (ver.1.0) 04 2024

Health & Fitness

Education

RSS

All content for Immuno Oncology Talks is the property of Sanofi and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Health & Fitness

Education

Therapeutic RNA vaccines in cancer Immunotherapy

Immuno Oncology Talks

29 minutes

2 years ago

Therapeutic RNA vaccines in cancer Immunotherapy

This episode, the seventh of our “Immuno Oncology Talks”, will be covering “Therapeutic RNA vaccines in cancer immunotherapy”, with our two guests, Professor Karine Breckpot and Professor Kris Thielemans, from the Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, in Belgium. Both experts have a long background within innovative immunotherapy strategies in cancer, and especially within mRNA vaccination. Professor Thielemans and his tea...